ORAMED PHARMACEUTICALS INC.— Sankey Diagram

Quarterly mode · period ending 2025-12-31 · SEC EDGAR

ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)
Revenue
$2M
↑+49.3% +$660Kvs FY2023 (Q1+Q2+Q3+Q4)
Gross Profit
$13K
↓-99.0% -$1Mvs FY2023 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025 (Q1+Q2+Q3+Q4)FY2023 (Q1+Q2+Q3+Q4)
Revenue$2M$1M
COGS$2M$0
Gross Profit$13K$1M
R&D$6M$9M
SG&A$0$0
D&A$121K$196K
Other OpEx$0$0
Operating Income$0$0
Interest Exp.$0$0
Other Non-Op$0$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · ORMP · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)